Author:
Di Cresce Christine,Way Colin,Rytelewski Mateusz,Vareki Saman Maleki,Nilam Supritha,Vincent Mark D.,Koropatnick James,Ferguson Peter J.
Publisher
Springer Berlin Heidelberg
Reference268 articles.
1. Aagaard L, Rossi JJ (2007) RNAi therapeutics: principles, prospects and challenges. Adv Drug Deliv Rev 59:75–86
2. Abbott DW, Freeman ML, Holt JT (1998) Double-strand break repair deficiency and radiation sensitivity in BRCA2 mutant cancer cells. J Natl Cancer Inst 90:978–985
3. Acsadi G, Dickson G, Love DR et al (1991) Human dystrophin expression in mdx mice after intramuscular injection of DNA constructs. Nature 352:815–818
4. Adjei AA, Dy GK, Erlichman C et al (2003) A phase I trial of ISIS 2503, an antisense inhibitor of H-ras, in combination with gemcitabine in patients with advanced cancer. Clin Cancer Res 9:115–123
5. Advani R, Peethambaram P, Lum BL et al (2004) A Phase II trial of aprinocarsen, an antisense oligonucleotide inhibitor of protein kinase C alpha, administered as a 21-day infusion to patients with advanced ovarian carcinoma. Cancer 100:321–326
Cited by
2 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献